Descriptive Research Reports

Descriptive Research Reports describe new, improved or innovative roles or services in managed care pharmacy practice that are of such importance that they should be brought to the attention of other pharmacy professionals. The following posters were selected for presentation:

**PRR-01:** Association Between Medication Non-Adherence and Indirect Costs Among Patients with GERD, Sanjeev Balu, PhD, MBA, Associate Director Health Outcomes, Eisai, Inc.

**PRR-02:** Clinical and Economic Outcomes in Patients with Type 2 Diabetes Initiating Insulin Glargine Using Disposable Pen Versus Exenatide, Onur Baser, PhD, MS, President, STATinMED Research

**PRR-03:** Risk of Venous Thromboembolism and Prophylaxis Use in Hospitalized Medically Ill US Patients up to 180 Days Post-Hospital Discharge, Onur Baser, PhD, MS, President, STATinMED Research

**PRR-04:** Dosing Patterns During First 18 Months of Infliximab Treatment in Patients with Rheumatoid Arthritis, Susan Bolge, PhD, Associate Director, Health Economics and Outcomes Research, Centocor Ortho Biotech Services, LLC

**PRR-05:** Time Between Infusions During First 18 Months of Infliximab Treatment in Patients with Rheumatoid Arthritis, Susan Bolge, PhD, Associate Director, Health Economics and Outcomes Research, Centocor Ortho Biotech Services, LLC

**PRR-06:** Baseline Characteristics of Patients with Rheumatoid Arthritis Initiating Anti-TNF Therapy, Susan Bolge, PhD, Associate Director Health Economics and Outcomes Research, Centocor Ortho Biotech Services, LLC

**PRR-07:** Barriers and Facilitators for Medication Adherence, Richard Bruzek, PharmD, Vice President Pharmacy Services, HealthPartners

**PRR-08:** Consistency of Maintenance Infliximab Weight-Based Dosing and Administration Patterns in Commercially Insured Patients with Rheumatoid Arthritis, Chureen Carter, PharmD, MS, Associate Director, Health Economics and Outcomes Research, Centocor Ortho Biotech Services, LLC

**PRR-09:** Healthcare Cost Outcomes for Alcohol Dependence: A Comparison of Four Treatments, Mady Chalk, PhD, Director, Center for Policy Research and Analysis Treatment Research Institute, Inc.
PRR-10: Painful Diabetic Neuropathy Newly Prescribed Pregabalin or Gabapentin in Usual Care Settings, Arthi Chandran, MS, MPH, Associate Director, Pfizer Inc.


PRR-12: Patterns of Atypical Antipsychotic Therapy Use in Adults with Bipolar I Disorder, Wenjia Chen, MS, Research Fellow, Rutgers, The State University of New Jersey

PRR-13: Investigating Risk Factors and Healthcare Costs Associated with Patients with Gout: Optimal Time to Initiate Urate-Lowering Therapy, I-Ning Cheng, MS, Clinical Pharmacy Specialist, HealthCare Partners Medical Group

PRR-14: Association of Chemotherapy-Induced Peripheral Neuropathy with Chemotherapy Treatment and Costs for Metastatic Breast Cancer Patients: A Claims Database Analysis, Stacey DaCosta Byfield, PhD, MPH, Senior Researcher, i3 Innovus

PRR-15: Utilization of Atypical Antipsychotic Treatment Among Adults with Schizophrenia, Angela DeVeaug-Geiss, PhD, Manager, Global Health Outcomes, Merck & Co., Inc.

PRR-16: Impact of Formulary Tier Down-Shift for Erlotinib on Copays and Treatment Behavior in Patients with Lung Cancer, Nicole Engel-Nitz, PhD, Researcher, i3 Innovus

PRR-17: Real-World Clinical Outcomes and Costs in Atrial Fibrillation/Flutter Patients on Combined Warfarin and Antiarrhythmic Drug Therapy, Annie Guerin, MSc, Senior Economist, Analysis Group, Inc.


PRR-19: Total Medical Cost of Care Claims Analysis for Patients Receiving Chemotherapy for Non-Small Cell Lung Cancer (NSCLC), Rex Force, PharmD, Professor and Consulting Partner, Idaho State University, improveRX, LLC

PRR-20: Modeled Effect of Generic Docetaxel on Total Medical Cost of Care With Taxanes in Metastatic Breast Cancer, Rex Force, PharmD, Professor and Consulting Partner, Idaho State University, ImproveRx, LLC

PRR-21: Use of Antidepressants and Atypical Antipsychotics in Patients with Pseudobulbar Affect, Andrea Formella, PharmD, BCPP, CMPP, Senior Medical Science Liaison, Avanir Pharmaceuticals
**PRR-22**: Optimum Time Post-Index Fill to Administer the Adherence Estimator: A Brief Proximal Screener for Patient Propensity to Adhere to Prescription Medications, Abhijit Gadkari, BSPharmacy, PhD, Manager US Outcomes Research, Merck & Co., Inc.

**PRR-23**: Determinants of Nonadherence to Prescription Medications for Diabetes and Lipid-Related Conditions: A Systematic Review, Abhijit Gadkari, BSPharmacy, PhD, Manager US Outcomes Research, Merck & Co., Inc.

**PRR-24**: Early and Sustained Remission Associated with Normalized Physical Function and Health-Related Quality of Life and Significantly Improved Productivity in Patients with Active Psoriatic Arthritis Treated with Golimumab: GO-REVEAL 2-Year Data, Timothy Gathany, MS, Analyst, Health Economics Pricing, Centocor Ortho Biotech Services, LLC

**PRR-25**: Cost of Warfarin-Associated Bleeding in Atrial Fibrillation, Sameer Ghate, BSPharmacy, MSPH, Research Associate, Adjunct Assistant Professor, University of Utah, College of Pharmacy

**PRR-26**: Diabetes Medication Adherence Association with Hospitalizations and Total Cost of Care, Patrick Gleason, PharmD, BCPS, FCCP, Director of Clinical Outcomes Assessment, Prime Therapeutics LLC

**PRR-27**: Impact of a Rosiglitazone Safety Edit: Cohort Study, Patrick Gleason, PharmD, BCPS, FCCP, Director of Clinical Outcomes Assessment, Prime Therapeutics LLC

**PRR-28**: Impact of a Clopidogrel and Proton Pump Inhibitor Concurrent Use Retrospective Drug Utilization Review Provider Safety Letter, Patrick Gleason, PharmD, BCPS, FCCP, Director of Clinical Outcomes Assessment, Prime Therapeutics LLC

**PRR-29**: Metastatic Renal Cell Carcinoma: Patient Characteristics and Recent Treatment Patterns in Real World Practice, Gregory Hess, MD, MBA, Vice President and Chief Medical Officer, SDI Health

**PRR-30**: Patient Compliance with Metastatic Renal Cell Carcinoma Treatments, Gregory Hess, MD, MBA, Vice President and Chief Medical Officer, SDI Health

**PRR-31**: Outcomes of a Retrospective Drug Utilization Review for High Risk Diabetics Not on Concurrent Hypertensive Therapy, Julie Huang, PharmD, Clinical Program Manager, MedImpact Healthcare Systems, Inc.

**PRR-32**: Health-Related Characteristics of Low Versus Normal Folate Level Women of Child-Bearing Age, Vijay Joish, PhD, Deputy Director, Bayer Healthcare Pharmaceuticals, Inc.

**PRR-33**: Impact of Prescription Cost-Sharing on Adherence to HIV Antiretroviral Therapy, Timothy Juday, PhD, Associate Director, Bristol-Myers Squibb
Prr-34: Impact of Multiple Sclerosis on Patients: A Systematic Review of the Evidence, Nipun Atreja, BS, MS Candidate, Duquesne University

Prr-35: A Systematic Review of the Impact of Treatments on Quality of Life, Work Productivity, and Adherence in Multiple Sclerosis, Nipun Atreja, BS, MS Candidate, Duquesne University

Prr-36: Examining Healthcare Costs in Chemotherapy Induced Nausea and Vomiting: A Retrospective Analysis, Russell Knoth, PhD, Associate Director, US Health Outcomes, Eisai, Inc.

Prr-37: Costs of Contraceptive Coverage and Pregnancy Care: An Actuarial Analysis, Amy Law, PharmD, MS, Deputy Director, Health Economics and Outcomes Research, Bayer Healthcare Pharmaceuticals, Inc.

Prr-38: Adherence to Antiretroviral Therapy and the Association with Risk of Hospitalization Among Commercially Insured HIV Patients in the United States, Juliana Meyers, MA, Associate Director, Health Economics, RTI Health Solutions

Prr-39: Exenatide BID Observational Study: Results for Primary and Secondary Endpoints at 12-Months Analysis, Lesley-Ann Miller, MS, PhD, Research Scientist, Lilly USA, LLC

Prr-40: Long-Term Consequences and Costs Associated with Venous Thromboembolism, Samir Mody, PharmD, MBA, Director, Translational Science Team in the Health Economics and Outcomes Research, Ortho-McNeil Janssen Scientific Affairs

Prr-41: Assessing Self-Reported Quality-of-Life and Productivity Among Employees with Select Auto-Immune Inflammatory Disorders, Ahmad Naim, MD, Associate Director, Health Economics and Outcomes Research, Centocor Ortho Biotech Services, LLC

Prr-42: To Total Burden of Illness for an Employed Population with Chronic Obstructive Pulmonary, Ken Wong, PharmD, Director, Outcomes Research, Novartis Pharmaceuticals

Prr-43: The National Breakthrough Pain Survey (NBTPS): Assessment of Quality-of-Life, Functioning, Productivity, and Healthcare Utilization, Arvind Narayana, MD, MBA, Medical Director, Cephalon Pain Franchise, Department of Medical Affairs, Cephalon, Inc.

Prr-44: Participant Characteristics Associated with Medication Adherence, Pamala Pawloski, PharmD, Research Investigator, HealthPartners Research Foundation

Prr-45: Real World Evaluation of the Cost Effectiveness of Prophylactic Treatment in the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer: Dalteparin Versus Enoxaparin, Annette Powers, PharmD, MBA, Director, Health Outcomes, Eisai, Inc.
PRR-46: The Incidence of Hypoglycemia and Resulting Impact on Direct Medical Costs in Type 2 Diabetes, Brian Quilliam, PhD, RPh, Associate Professor, University of Rhode Island, College of Pharmacy

PRR-47: Comparison of Healthcare Costs for Gout Patients by Uric Acid Level, Karen Rascati, PhD, Professor, The University of Texas at Austin, College of Pharmacy

PRR-48: Encouraging Generic Alternatives in Medicare Part D Through Member Outreach, Brian Roman, PharmD, RPh, Director, Analytics and Outcomes, CVS Caremark

PRR-49: The Relationship Between Buprenorphine-Medication Assisted Treatment Adherence and Healthcare Costs and Service Utilization: An Analysis of Aetna’s Opioid Dependent Members, Charles Ruetsch, PhD, President and Chief Science Officer, Health Analytics, LLC

PRR-50: Evaluation of a Pharmacist-Led Medication Reconciliation Program in Post-Discharge Patients, Sheila Salamunovich, PharmD, Clinical Pharmacy Specialist, HealthCare Partners Medical Group

PRR-51: Health Care Utilization and Costs During the First 3 Years After a Health Care Utilization and Costs During the First 3 Years After a Diagnosis of Fibromyalgia, Robert Sanchez, RPh, MSc, Director, Health Economics and Outcomes Research, Pfizer Inc.

PRR-52: Adherence, Persistence and Medical Costs Associated with the Use of Clinically Effective Doses of Antipsychotic Medications in Patients with Bipolar Disorder, Kafi Sanders, MPH, Associate Director of Outcomes Research, Pfizer Inc.

PRR-53: Multiple Sclerosis Medical and Pharmacy Cost Trends 2006 to 2009, Jeremy Schafer, PharmD, MBA, Senior Director of Utilization Management, Prime Therapeutics LLC

PRR-54: Healthcare Costs of Patients Switching or Dose Escalating Anti-Tumor Necrosis Factor Therapy, Cynthia Schmeichel, MS, PhD, Associate Director, Translational Science, Centocor Ortho Biotech Services, LLC

PRR-55: Characterization of Baseline Differences in Adult Patients with Rheumatoid Arthritis Initiating Anti-TNF Therapy, Cynthia Schmeichel, MS, PhD, Associate Director, Translational Science, Centocor Ortho Biotech Services, LLC

PRR-56: Assessment of Medication Utilization Before and After Initiation of Pregabalin Utilizing a Pharmacy Claims Database, Nicholas Schnarr, PharmD, Clinical Pharmacist, Formulary Services, informedRx

PRR-57: Direct Healthcare and Workplace Productivity Costs of Back and Neck Pain with or Without a Neuropathic Component Compared to Other Medical Conditions in a Large Integrated Database for 2005 and 2007, Robert Simons, PhD, President, Global Health Economics & Outcomes Research, Inc.
PRR-58: Patterns of Thromboprophylaxis Use in Patients Undergoing Total Hip and Knee Replacement Surgery in a Large US Health Plan, Donna Spencer, PhD, Associate Director, Health Economics and Outcomes Research, i3 Innovus

PRR-59: Low Montelukast (Singulair) Persistence Regardless of Diagnosis: Utilization Management Opportunity, Catherine Starner, PharmD, Senior Clinical Pharmacist, Prime Therapeutics LLC

PRR-60: Economic Impact of Suboptimal Treatment Response with Second-Generation Antidepressant Therapy in Major Depressive Disorder, Matthew Sussman, MA, Research and Marketing Associate, Boston Health Economics, Inc.

PRR-61: Evaluation of PQA Draft Measures of MTM Performance, David Nau, PhD, RPh, Senior Director, PQA, Inc.

PRR-62: Healthcare Resource Utilization and Costs Among Type 2 Diabetes Mellitus Patients on Combination Oral Therapy: Step-Therapy, Loose and Fixed Dose Combinations, Setareh Williams, PhD, Director, Health Economics and Outcomes Research, AstraZeneca

PRR-63: Patterns of Osteoporosis Treatment Change in a Medicare Advantage Prescription Drug (MAPD) Plan, Yihua Xu, PhD, Research Scientist, Humana, Inc.

PRR-64: Healthcare Resource Utilization and Costs Associated with Bevacizumab Versus Cetuximab in Second-line Treatment of Metastatic Colorectal Cancer Patients, Hongbo Yang, Associate, Analysis Group, Inc.